Inve India ▾

Hikal share price & results

Hikal Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

CDMO maker of APIs, intermediates and crop-protection chemicals for global pharma and agrochem innovators.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue403 ₹ crore+5.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin9.2 %+2.6 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-7.4 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity3.44 %−5.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin8.99 %+1.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-5.37 %−12.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 9 judged targets kept · 17 open · verdicts reflect calls analysed to Q1 FY27.

Hikal Limited management guidance track record on Inve: 26 targets tracked across analysed earnings calls (4 achieved, 5 missed, 17 open).

TargetOriginal wordingSaidLatest callVerdict
Crop Protection Revenue GrowthMuted/Flattish in FY26
Call transcript, Q4 FY25 · 14 May 2025		Q4 FY25Q1 FY27:Promise pertains to FY26, which is complete. Verdict stands.
Call transcript, Q1 FY27 · 6 Aug 2026		Achieved
Pharma Business Revenue Growth12-15% growth in FY26
Call transcript, Q4 FY25 · 14 May 2025		Q4 FY25Q1 FY27:Promise pertains to FY26, which is complete. Verdict stands.
Call transcript, Q1 FY27 · 6 Aug 2026		Missed
Completion of CAPA for US FDA OAIRemaining balance to be closed out before end of this quarter (Sept 2025)
Call transcript, Q1 FY26 · 7 Aug 2025		Q1 FY26Q1 FY27:Timeline pushed further. Management now expects re-inspection 'towards the end of this financial year' (FY27), a delay from the previous 'end of 2026' guidance.
Call transcript, Q1 FY27 · 6 Aug 2026		Delayed

Source: Inve Guidance Tracker for Hikal Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Hikal Limited's 26 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 23 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹201.83 +3.53% · +₹6.89

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −16.9% 1Y

₹150₹200₹250Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 11 Feb 2026Q4 FY26 — 27 May 2026Q1 FY27 — 6 Aug 2026

1Y: ₹243 on 24 Oct 2025 → ₹201.83. High ₹256.15 (10 Dec 2025), low ₹147.08 (30 Mar 2026).

Previous close
₹194.94
Market cap
₹2.4k Cr
52-week range
₹147.08 – ₹256.15
One year
−16.81%
Price to earnings (TTM to Jun 2026)
56.32×
Return on equity (TTM to Jun 2026)
3.44%

Overview

Symbol
NSE:HIKAL
Exchange
NSE
Currency
INR

What Hikal Limited does

Based on the company's own presentations, annual report and earnings calls.

Hikal Limited is an Indian specialty chemicals manufacturer that makes active pharmaceutical ingredients (APIs), advanced intermediates and crop-protection actives, largely under long-term contract development and manufacturing (CDMO) arrangements with global pharmaceutical and agrochemical innovators. It runs cGMP, US FDA-approved plants at Jigani (Bengaluru, Karnataka) and Panoli (Gujarat) for pharmaceuticals, and separate facilities at Mahad, Taloja (Maharashtra) and Panoli for crop-protection chemicals, backed by a Research & Technology centre in Pune. Beyond its two core segments it is building out newer Animal Health, Specialty Chemicals and Personal Care ingredient lines for the same innovator-customer base.

Segments

  • Pharmaceuticals
  • Crop Protection
Employees
3,000+
Pharmaceuticals manufacturing facilities
5 (Jigani Unit 1 & 2, Bengaluru, Karnataka; Panoli, Gujarat)
Crop Protection manufacturing facilities
3 (Mahad and Taloja, Maharashtra; Panoli, Gujarat)
Active DMFs (Drug Master Files) filed
74
Commercialised APIs
31
Commercialised Crop Protection products
31
Founded 1988Headquarters Mumbai, Maharashtra, India Company website

How the price took the results

close before → close after

Q1 FY27
−4.8%
6 Aug
Q4 FY26
+1.5%
27 May
Q3 FY26
+0.8%
11 Feb
Q2 FY26
+0.8%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Hikal Limited

Free account: one company. Everything above stays public.

Write why you follow Hikal Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Hikal Limited

Guides on how to read this kind of business and the numbers that matter.